CLOs on the Move

Nautilus Biosciences Canada

www.nautilusbiosci.com

 
Nautilus Biosciences Canada is a Charlottetown, PE-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Foamix

Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology.

ServRx

ServRx is a leading national workers` compensation prescription drug claims processing company. With a strong backbone of proprietary IT and decades of experience in the workers` compensation space, ServRx serves a rapidly growing share of community and independent pharmacies. Across America, each pharmacy client is as unique as the injured workers they treat. ServRx prides itself on creating customized solutions to meet the needs of our diverse client-base. Rural mom-and-pop pharmacies, regional chains, specialty pharmacies, and large pharmacy management firms alike have turned to ServRx to handle the unique workflow and cash-flow challenges posed by workers` compensation. A winning mix of experience, technology, and economies of scale allows ServRx to promise its clients superior handling of their workers` compensation claims. Whether they process one pharmacy claim per week, or hundreds per day, ServRx clients have something in common: peace of mind and increased profitability.

Foot & Ankle Specialists of the Mid-Atlantic

Need a podiatrist? Foot & Ankle Specialists of the Mid-Atlantic has offices all along the east coast. Contact our doctors today for additional help & information!

WuXi AppTec

WuXi AppTec, Inc. is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Galmed Pharmaceuticals

Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis, or NASH, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. Galmed Pharmaceuticals Galmed’s business has been, in its current legal structure, was incorporated in Israel on July 31, 2013 as a privately held company. However, operating since 2000 under a different group of companies established in the same year. Galmed was co-founded by Professor Tuvia Gilat and Allen Baharaff, based on Professor Gilat’s extensive research in FABAC’s and NASH.